FDA Approves TNKase for Acute Ischemic Stroke
By Lori Solomon HealthDay Reporter
THURSDAY, March 6, 2025 -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a 60-minute infusion. Genentech, the manufacturer of TNKase, says a new 25-mg vial configuration will be available in the coming months.
The approval is based on a study comparing TNKase to Activase in patients with acute ischemic stroke who presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
Stroke affects more than 795,000 people each year in the United States. It is the leading cause of long-term disability and the fifth leading cause of death. Since brain damage occurs and progresses rapidly during an acute ischemic stroke, immediate, fast-acting medical care is vital.
"Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients," Levi Garraway, M.D., Ph.D., the chief medical officer and head of global product development at Genentech, said in a statement. "TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke."
Approval of TNKase was granted to Genentech.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
FRIDAY, March 7, 2025 -- The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more affordable for people...
Stillbirth Rates Are Highest in the South
FRIDAY, March 7, 2025 -- Women in the U.S. South are three times more likely to lose a baby in late pregnancy than mothers in other regions, a new study reports. The study...
This Score Can Predict Risk of Early Colon Cancer
FRIDAY, March 7, 2025 — A new risk prediction model can help identify people who are likely to develop early-onset colon cancer or small non-cancerous growths on other...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.